Revision as of 20:47, 6 November 2012 by Raviteja Reddy Guddeti(talk | contribs)(/* Preoperative Evaluation (DO NOT EDIT){{cite journal| author=Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE et al.| title=2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients ...)
Indications for surgical repair of a thoracic aortic aneurysm include rupture; symptoms such as pain consistent with impending rupture; aortic regurgitation; growth ≥ 0.5 - 1 cm/year; bicuspid aortic valve; asymptomatic patients with degenerative thoracic aneurysm, chronic aortic dissection, intramural hematoma, penetrating atherosclerotic ulcer, mycotic aneurysm, or pseudoaneurysm, who are otherwise suitable candidates once a TAA reaches a pre-specified size (>5 cm in the ascending aorta, >6 cm in the descending segment) referral for surgical or endovascular repair sholuld be initiated. Most patients undergo repair once they reach >5.5 cm diameter in the ascending aorta and > 6.5 cm in the descending thoracic aorta, respectively. Patients with Marfan syndrome or other genetically mediated disorders (vascular Ehlers-Danlos syndrome, Turner syndrome, bicuspid aortic valve, or familial thoracic aortic aneurysm and dissection) should undergo elective operation at smaller diameters (4.0 to 5.0 cm depending on the condition. To avoid acute dissection or rupture, adult patients with Loeys-Dietz syndrome should undergo surgery for an aortic diameter of >4.4 to 4.6 cm. If a Marfan syndrome patient is contemplating pregnancy, they should undergo aortic root replacement if the diameter is greater than 4 cm, and patients undergoing aortic valve repair or replacement and who have an ascending aorta or aortic root of greater than 4.5 cm should be considered for concomitant repair of the aortic root or replacement of the ascending aorta. A woven dacron tube graft is most commonly used in the repair of thoracic aortic aneurysms.
Evaluating The Patient's Risk Of Dissection And Rupture
The annual risk of rupture is closely related to aneurysm size (3% for TAAs <4 cm and 7% for >6 cm). Shown below is the annual risk of thoracic aortic rupture, dissection or death for different diameters of thoracic aortic aneurysms. The curvilinear nature of the risk of cardiovascular events forms the basis for performing surgery when the aorta is 5.0 to 6 cm in diameter depending upon whether the patient has Marfan syndrome or Loeys-Dietz syndrome or not.
Once a thoracic aortic aneurysm is identified, the patient should be followed with clinical and noninvasive testing every three months and then every six months for yearly thereafter.
Immediate surgical repair is recommended, as this condition is associated with faster rate of aortic dilatation [1]
Absolute size
Marfan's
Non-Marfan's
Ascending aorta
5.0 cm
5.5 cm
Descending aorta
6.0 cm
6.5 cm
Patients with Marfan syndrome or other genetically mediated disorders (vascular Ehlers-Danlos syndrome, Turner syndrome, bicuspid aortic valve, or familial thoracic aortic aneurysm and dissection) should undergo elective operation at smaller diameters (4.0 to 5.0 cm depending on the condition; to avoid acute dissection or rupture
Adult patients with Loeys-Dietz syndrome should undergo surgery for an aortic diameter of >4.4 to 4.6 cm
If Marfan syndrome patient is contemplating pregnancy, they should undergo aortic root replacement if the diameter is greater than 4 cm.
Asymptomatic patients with degenerative thoracic aneurysm, chronic aortic dissection, intramural hematoma, penetrating atherosclerotic ulcer, mycotic aneurysm, or pseudoaneurysm, who are otherwise suitable candidates and for whom the ascending aorta or aortic sinus diameter is 5.5 cm or greater should be evaluated for surgical repair
Patients undergoing aortic valve repair or replacement and who have an ascending aorta or aortic root of greater than 4.5 cm should be considered for concomitant repair of the aortic root or replacement of the ascending aorta
Surgery for Thoracic aortic aneurysm
The choice of operation depends on-
Underlying pathology
Extent of the disease (both proximally and distally)
Patient's life expectancy
Desired anti-coagulation status
Ascending aortic aneurysms
Ascending aorta with normal aortic valves, annulus and sinus of Valsalva
Simple dacron tube graft
Diseased aortic valve and normal sinus and annulus
Replace aortic valve separately from repair of aneurysm (with supracoronary synthetic graft)
Normal valves with aneurysmal sinus and aortic insufficiency
1) Remodelling method: resecting the sinus tissue and repair with dacron graft to form new sinus
2) Re-imaplantation method: reimplanting the scalloped valve with dacron graft
Diseased aortic valve and diseased aortic root
Aortic root replacement. Younger individuals: composite valve graft consisting of mechanical valve inserted into a Dacron graft coronary artery reimplantation. Older individuals, women of child bearing age, those with contraindications to use of warfarin: aortic homografts, pulmonary autografts
Myocardial infarction due to technical problems with coronary ostia implantation during root replacement for ascending aortic aneurysms; may require reoperation
"1. Asymptomatic patients with degenerative thoracic aneurysm, chronic aortic dissection, intramural hematoma, penetrating atherosclerotic ulcer, mycotic aneurysm, or pseudoaneurysm, who are otherwise suitable candidates and for whom the ascending aorta or aortic sinus diameter is 5.5 cm or greater should be evaluated for surgical repair. (Level of Evidence: A)"
"3. Patients with a growth rate of more than 0.5 cm/y in an aorta that is less than 5.5 cm in diameter should be considered for operation. (Level of Evidence: C)"
"4. Patients undergoing aortic valve repair or replacement and who have an ascending aorta or aortic root of greater than 4.5 cm should be considered for concomitant repair of the aortic root or replacement of the ascending aorta. (Level of Evidence:C)"
"1. Elective aortic replacement is reasonable for patients with Marfan syndrome, other genetic diseases, or bicuspid aortic valves, when the ratio of maximal ascending or aortic root area (πr2) in cm2 divided by the patient's height in meters exceeds 10[11][12]. (Level of Evidence:C)"
"1. Patients with symptoms suggestive of expansion of a thoracic aneurysm should be evaluated for prompt surgical intervention unless life expectancy from comorbid conditions is limited or quality of life is substantially impaired. (Level of Evidence: A)"
Open Surgery for Ascending Aortic Aneurysm (DO NOT EDIT)[2]
"1. Separate valve and ascending aortic replacement are recommended in patients without significant aortic root dilatation, in elderly patients, or in young patients with minimal dilatation who have aortic valve disease. (Level of Evidence: C)"
"1. For thoracic aortic aneurysms also involving the proximal aortic arch, partial arch replacement together with ascending aorta repair using right subclavian/axillary artery inflow and hypothermic circulatory arrest is reasonable[17][18][19]. (Level of Evidence:B)"
"2. Replacement of the entire aortic arch is reasonable for acute dissection when the arch is aneurysmal or there is extensive aortic arch destruction and leakage[18][19]. (Level of Evidence:B)"
"3. Replacement of the entire aortic arch is reasonable for aneurysms of the entire arch, for chronic dissection when the arch is enlarged, and for distal arch aneurysms that also involve the proximal descending thoracic aorta, usually with the elephant trunk procedure[20][21][22]. (Level of Evidence:B)"
"4. For patients with low operative risk in whom an isolated degenerative or atherosclerotic aneurysm of the aortic arch is present, operative treatment is reasonable for asymptomatic patients when the diameter of the arch exceeds 5.5 cm[23]. (Level of Evidence:B)"
"5. For patients with isolated aortic arch aneurysms less than 4.0 cm in diameter, it is reasonable to reimage using computed tomographic imaging or magnetic resonance imaging, at 12-month intervals, to detect enlargement of the aneurysm. (Level of Evidence:C)"
"1. For patients with chronic dissection, particularly if associated with a connective tissue disorder, but without significant comorbid disease, and a descending thoracic aortic diameter exceeding 5.5 cm, open repair is recommended[4][24][25]. (Level of Evidence: B)"
"2. For patients with degenerative or traumatic aneurysms of the descending thoracic aorta exceeding 5.5 cm, saccular aneurysms, or postoperative pseudoaneurysms, endovascular stent grafting should be strongly considered when feasible[4][26]. (Level of Evidence: B)"
"3. For patients with thoracoabdominal aneurysms, in whom endovascular stent graft options are limited and surgical morbidity is elevated, elective surgery is recommended if the aortic diameter exceeds 6.0 cm, or less if a connective tissue disorder such as Marfan or Loeys-Dietz syndrome is present[4]. (Level of Evidence: C)"
"4. For patients with thoracoabdominal aneurysms and with end-organ ischemia or significant stenosis from atherosclerotic visceral artery disease, an additional revascularization procedure is recommended[27]. (Level of Evidence:B)"
"1. In preparation for surgery, imaging studies adequate to establish the extent of disease and the potential limits of the planned procedure are recommended. (Level of Evidence: C) "
"2. Patients with thoracic aortic disease requiring a surgical or catheter-based intervention who have symptoms or other findings of myocardial ischemia should undergo additional studies to determine the presence of significant coronary artery disease. (Level of Evidence: C)"
"3. Patients with unstable coronary syndromes and significant coronary artery disease should undergo revascularization prior to or at the time of thoracic aortic surgery or endovascular intervention with percutaneous coronary intervention or concomitant coronary artery bypass graft surgery. (Level of Evidence: C)"
"1. For patients who are to undergo surgery or endovascular intervention for descending thoracic aortic disease, and who have clinically stable, but significant (flow limiting), coronary artery disease, the benefits of coronary revascularization are not well established[28][29][30]. (Level of Evidence: B)"
Choice of Anesthetic and Monitoring Techniques (DO NOT EDIT) [2]
"1. The choice of anesthetic techniques and agents and patient monitoring techniques should be tailored to individual patient needs to facilitate surgical and perfusion techniques and the monitoring of hemodynamics and organ function. (Level of Evidence: C) "
"2. Routinely changing double-lumen endotracheal (endobronchial) tubes to single-lumen tubes at the end of surgical procedures complicated by significant upper airway edema or hemorrhage is not recommended. (Level of Evidence: C) "
"1.Transesophageal echocardiography is reasonable in all open surgical repairs of the thoracic aorta, unless there are specific contraindications to its use. Transesophageal echocardiography is reasonable in endovascular thoracic aortic procedures for monitoring, procedural guidance, and/or endovascular graft leak detection. (Level of Evidence: B)"
"2. Motor or somatosensory evoked potential monitoring can be useful when the data will help to guide therapy. It is reasonable to base the decision to use neurophysiologic monitoring on individual patient needs, institutional resources, the urgency of the procedure, and the surgical and perfusion techniques to be employed in the open or endovascular thoracic aortic repair. (Level of Evidence: B)"
Transfusion Management and Anticoagulation in Thoracic Aortic Surgery (DO NOT EDIT) [2]
"1. An algorithmic approach to transfusion, antifibrinolytic, and anticoagulation management is reasonable to use in both open and endovascular thoracic aortic repairs during the perioperative period. Institutional variations in coagulation testing capability and availability of transfusion products and other prothrombotic and antithrombotic agents are important considerations in defining such an approach. (Level of Evidence: C) "
Brain Protection during Ascending Aortic and Transverse Aortic Arch Surgery (DO NOT EDIT) [2]
"1. A brain protection strategy to prevent stroke and preserve cognitive function should be a key element of the surgical, anesthetic, and perfusion techniques used to accomplish repairs of the ascending aorta and transverse aortic arch. (Level of Evidence: B) "
"1. Perioperative brain hyperthermia is not recommended in repairs of the ascending aortic and transverse aortic arch as it is probably injurious to the brain. (Level of Evidence: B)"
"1. Deep hypothermic circulatory arrest, selective antegrade brain perfusion, and retrograde brain perfusion are techniques that alone or in combination are reasonable to minimize brain injury during surgical repairs of the ascending aorta and transverse aortic arch. Institutional experience is an important factor in selecting these techniques. (Level of Evidence: B) "
Spinal Cord Protection during Descending Aortic Open Surgical and Endovascular Repairs (DO NOT EDIT) [2]
"1. Cerebrospinal fluid drainage is recommended as a spinal cord protective strategy in open and endovascular thoracic aortic repair for patients at high risk of spinal cord ischemic injury. (Level of Evidence: B) "
"1. Spinal cord perfusion pressure optimization using techniques, such as proximal aortic pressure maintenance and distal aortic perfusion, is reasonable as an integral part of the surgical, anesthetic, and perfusion strategy in open and endovascular thoracic aortic repair patients at high risk of spinal cord ischemic injury. Institutional experience is an important factor in selecting these techniques. (Level of Evidence: B) "
"2. Moderate systemic hypothermia is reasonable for protection of the spinal cord during open repairs of the descending thoracic aorta. (Level of Evidence: B) "
"1. Adjunctive techniques to increase the tolerance of the spinal cord to impaired perfusion may be considered during open and endovascular thoracic aortic repair for patients at high risk of spinal cord injury. These include distal perfusion, epidural irrigation with hypothermic solutions, high-dose systemic glucocorticoids, osmotic diuresis with mannitol, intrathecal papaverine, and cellular metabolic suppression with anesthetic agents. (Level of Evidence: B) "
"2. Neurophysiological monitoring of the spinal cord (somatosensory evoked potentials or motor evoked potentials) may be considered as a strategy to detect spinal cord ischemia and to guide reimplantation of intercostal arteries and/or hemodynamic optimization to prevent or treat spinal cord ischemia. (Level of Evidence: B) "
Renal Protection during Descending Aortic Open Surgical and Endovascular Repairs (DO NOT EDIT) [2]
"1. Preoperative hydration and intraoperative mannitol administration may be reasonable strategies for preservation of renal function in open repairs of the descending aorta. (Level of Evidence: C) "
"2. During thoracoabdominal or descending aortic repairs with exposure of the renal arteries, renal protection by either cold crystalloid or blood perfusion may be considered. (Level of Evidence: B) "
References
↑Tadros TM, Klein MD, Shapira OM (2009). "Ascending aortic dilatation associated with bicuspid aortic valve: pathophysiology, molecular biology, and clinical implications". Circulation. 119 (6): 880–90. doi:10.1161/CIRCULATIONAHA.108.795401. PMID19221231. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑ 2.002.012.022.032.042.052.062.072.082.092.102.11Hiratzka LF, Bakris GL, Beckman JA; et al. (2010). "2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine". Circulation. 121 (13): e266–369. doi:10.1161/CIR.0b013e3181d4739e. PMID20233780. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Gott VL, Greene PS, Alejo DE; et al. (1999). "Replacement of the aortic root in patients with Marfan's syndrome". N. Engl. J. Med. 340 (17): 1307–13. doi:10.1056/NEJM199904293401702. PMID10219065. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑ 4.04.14.24.3Svensson LG, Kouchoukos NT, Miller DC; et al. (2008). "Expert consensus document on the treatment of descending thoracic aortic disease using endovascular stent-grafts". Ann. Thorac. Surg. 85 (1 Suppl): S1–41. doi:10.1016/j.athoracsur.2007.10.099. PMID18083364. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Kouchoukos NT, Dougenis D (1997). "Surgery of the thoracic aorta". N. Engl. J. Med. 336 (26): 1876–88. doi:10.1056/NEJM199706263362606. PMID9197217. Unknown parameter |month= ignored (help)
↑Elefteriades JA (2002). "Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks". Ann. Thorac. Surg. 74 (5): S1877–80, discussion S1892–8. PMID12440685. Unknown parameter |month= ignored (help)
↑Boissonnas CC, Davy C, Bornes M; et al. (2009). "Careful cardiovascular screening and follow-up of women with Turner syndrome before and during pregnancy is necessary to prevent maternal mortality". Fertil. Steril. 91 (3): 929.e5–7. doi:10.1016/j.fertnstert.2008.09.037. PMID18990374. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Svensson LG, Kim KH, Lytle BW, Cosgrove DM (2003). "Relationship of aortic cross-sectional area to height ratio and the risk of aortic dissection in patients with bicuspid aortic valves". J. Thorac. Cardiovasc. Surg. 126 (3): 892–3. PMID14502185. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑Tzemos N, Therrien J, Yip J; et al. (2008). "Outcomes in adults with bicuspid aortic valves". JAMA. 300 (11): 1317–25. doi:10.1001/jama.300.11.1317. PMID18799444. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Vallely MP, Semsarian C, Bannon PG (2008). "Management of the ascending aorta in patients with bicuspid aortic valve disease". Heart Lung Circ. 17 (5): 357–63. doi:10.1016/j.hlc.2008.01.007. PMID18514024. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑Svensson LG, Khitin L (2002). "Aortic cross-sectional area/height ratio timing of aortic surgery in asymptomatic patients with Marfan syndrome". J. Thorac. Cardiovasc. Surg. 123 (2): 360–1. PMID11828302. Unknown parameter |month= ignored (help)
↑ 12.012.1Iribarren C, Sidney S, Sternfeld B, Browner WS (2000). "Calcification of the aortic arch: risk factors and association with coronary heart disease, stroke, and peripheral vascular disease". JAMA. 283 (21): 2810–5. PMID10838649. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑Loeys BL, Schwarze U, Holm T; et al. (2006). "Aneurysm syndromes caused by mutations in the TGF-beta receptor". N. Engl. J. Med. 355 (8): 788–98. doi:10.1056/NEJMoa055695. PMID16928994. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Vaughan CJ, Casey M, He J; et al. (2001). "Identification of a chromosome 11q23.2-q24 locus for familial aortic aneurysm disease, a genetically heterogeneous disorder". Circulation. 103 (20): 2469–75. PMID11369687. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Abedin M, Tintut Y, Demer LL (2004). "Vascular calcification: mechanisms and clinical ramifications". Arterioscler. Thromb. Vasc. Biol. 24 (7): 1161–70. doi:10.1161/01.ATV.0000133194.94939.42. PMID15155384. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑Chiu KM, Lin TY, Chen JS, Li SJ, Chan CY, Chu SH (2006). "Images in cardiovascular medicine. Left ventricle apical conduit to bilateral subclavian artery in a patient with porcelain aorta and aortic stenosis". Circulation. 113 (9): e388–9. doi:10.1161/CIRCULATIONAHA.105.548065. PMID16520418. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑Svensson LG, Blackstone EH, Rajeswaran J; et al. (2004). "Does the arterial cannulation site for circulatory arrest influence stroke risk?". Ann. Thorac. Surg. 78 (4): 1274–84, discussion 1274–84. doi:10.1016/j.athoracsur.2004.04.063. PMID15464485. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑ 18.018.1Crawford ES, Kirklin JW, Naftel DC, Svensson LG, Coselli JS, Safi HJ (1992). "Surgery for acute dissection of ascending aorta. Should the arch be included?". J. Thorac. Cardiovasc. Surg. 104 (1): 46–59. PMID1614214. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑ 19.019.1Svensson LG, Crawford ES, Hess KR, Coselli JS, Safi HJ (1990). "Dissection of the aorta and dissecting aortic aneurysms. Improving early and long-term surgical results". Circulation. 82 (5 Suppl): IV24–38. PMID2225411. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑Greenberg RK, Haddad F, Svensson L; et al. (2005). "Hybrid approaches to thoracic aortic aneurysms: the role of endovascular elephant trunk completion". Circulation. 112 (17): 2619–26. doi:10.1161/CIRCULATIONAHA.105.552398. PMID16246961. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Svensson LG (2005). "The elephant trunk procedure: uses in complex aortic diseases". Curr. Opin. Cardiol. 20 (6): 491–5. PMID16234619. Unknown parameter |month= ignored (help)
↑Svensson LG, Kim KH, Blackstone EH; et al. (2004). "Elephant trunk procedure: newer indications and uses". Ann. Thorac. Surg. 78 (1): 109–16, discussion 109–16. doi:10.1016/j.athoracsur.2004.02.098. PMID15223413. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Coady MA, Rizzo JA, Hammond GL; et al. (1997). "What is the appropriate size criterion for resection of thoracic aortic aneurysms?". J. Thorac. Cardiovasc. Surg. 113 (3): 476–91, discussion 489–91. PMID9081092. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Estrera AL, Rubenstein FS, Miller CC, Huynh TT, Letsou GV, Safi HJ (2001). "Descending thoracic aortic aneurysm: surgical approach and treatment using the adjuncts cerebrospinal fluid drainage and distal aortic perfusion". Ann. Thorac. Surg. 72 (2): 481–6. PMID11515886. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑Svensson LG, Crawford ES, Hess KR, Coselli JS, Safi HJ (1993). "Variables predictive of outcome in 832 patients undergoing repairs of the descending thoracic aorta". Chest. 104 (4): 1248–53. PMID8404201. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑Matsumura JS, Cambria RP, Dake MD, Moore RD, Svensson LG, Snyder S (2008). "International controlled clinical trial of thoracic endovascular aneurysm repair with the Zenith TX2 endovascular graft: 1-year results". J. Vasc. Surg. 47 (2): 247–257, discussion 257. doi:10.1016/j.jvs.2007.10.032. PMID18241743. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑Svensson LG, Crawford ES, Hess KR, Coselli JS, Safi HJ (1992). "Thoracoabdominal aortic aneurysms associated with celiac, superior mesenteric, and renal artery occlusive disease: methods and analysis of results in 271 patients". J. Vasc. Surg. 16 (3): 378–89, discussion 389–90. PMID1522640. Unknown parameter |month= ignored (help)CS1 maint: Multiple names: authors list (link)
↑Boden WE, O'Rourke RA, Teo KK; et al. (2007). "Optimal medical therapy with or without PCI for stable coronary disease". N. Engl. J. Med. 356 (15): 1503–16. doi:10.1056/NEJMoa070829. PMID17387127. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
↑Poldermans D, Schouten O, Vidakovic R; et al. (2007). "A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study". J. Am. Coll. Cardiol. 49 (17): 1763–9. doi:10.1016/j.jacc.2006.11.052. PMID17466225. Unknown parameter |month= ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
